The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.


Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
09 11 2019
Historique:
received: 16 09 2019
accepted: 25 10 2019
entrez: 11 11 2019
pubmed: 11 11 2019
medline: 26 9 2020
Statut: epublish

Résumé

All cancer cells need to maintain functional telomeres to sustain continuous cell division and proliferation. In human diffuse gliomas, functional telomeres are maintained due either to reactivation of telomerase expression, the main pathway in most cancer types, or to activation of a mechanism called the alternative lengthening of telomeres (ALT). The presence of IDH1/2 mutations (IDH-mutant) together with loss of ATRX expression (ATRX-lost) are frequently associated with ALT in diffuse gliomas. However, detection of ALT, and a fortiori its quantification, are rarely, if ever, measured in neuropathology laboratories. We measured the level of ALT activity using the previously described quantitative "C-circle" assay and analyzed it in a well characterized cohort of 104 IDH-mutant and ATRX-lost adult diffuse gliomas. We report that in IDH-mutant ATRX-lost anaplastic astrocytomas, the intensity of ALT was inversely correlated with age (p < 0.001), the younger the patient, the higher the intensity of ALT. Strikingly, glioblastomas having progressed from anaplastic astrocytomas did not exhibit this correlation. ALT activity level in the tumor did not depend on telomere length in healthy tissue cells from the same patient. In summary, we have uncovered the existence, in anaplastic astrocytomas but not in glioblastomas with the same IDH and ATRX mutations, of a correlation between patient age and the level of activity of ALT, a telomerase-independent pathway of telomere maintenance.

Identifiants

pubmed: 31706351
doi: 10.1186/s40478-019-0833-0
pii: 10.1186/s40478-019-0833-0
pmc: PMC6842523
doi:

Substances chimiques

IDH2 protein, human EC 1.1.1.41
Isocitrate Dehydrogenase EC 1.1.1.41
IDH1 protein, human EC 1.1.1.42.
ATRX protein, human EC 3.6.4.12
X-linked Nuclear Protein EC 3.6.4.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

175

Subventions

Organisme : Ligue Contre le Cancer
ID : Grand Ouest
Pays : International
Organisme : Fondation ARC pour la Recherche sur le Cancer
ID : subvention fixe
Pays : International
Organisme : Canceropôle Lyon Auvergne Rhone-Alpes (FR)
ID : Oncostarter
Pays : International
Organisme : Labex
ID : DEVweCAN
Pays : International
Organisme : Institut National Du Cancer
ID : POLA network
Pays : International

Investigateurs

C Desenclos (C)
H Sevestre (H)
P Menei (P)
A Rousseau (A)
T Cruel (T)
S Lopez (S)
M-I Mihai (MI)
A Petit (A)
C Adam (C)
F Parker (F)
P Dam-Hieu (P)
I Quintin-Roué (I)
S Eimer (S)
H Loiseau (H)
L Bekaert (L)
F Chapon (F)
D Ricard (D)
C Godfraind (C)
T Khalil (T)
D Cazals-Hatem (D)
T Faillot (T)
C Gaultier (C)
M C Tortel (MC)
I Carpiuc (I)
P Richard (P)
W Lahiani (W)
H Aubriot-Lorton (H)
F Ghiringhelli (F)
C A Maurage (CA)
C Ramirez (C)
E M Gueye (EM)
F Labrousse (F)
O Chinot (O)
L Bauchet (L)
V Rigau (V)
P Beauchesne (P)
G Gauchotte (G)
M Campone (M)
D Loussouarn (D)
D Fontaine (D)
F Vandenbos-Burel (F)
A Le Floch (A)
P Roger (P)
C Blechet (C)
M Fesneau (M)
A Carpentier (A)
J Y Delattre (JY)
S Elouadhani-Hamdi (S)
M Polivka (M)
D Larrieu-Ciron (D)
S Milin (S)
P Colin (P)
M D Diebold (MD)
D Chiforeanu (D)
E Vauleon (E)
O Langlois (O)
A Laquerriere (A)
F Forest (F)
M J Motso-Fotso (MJ)
M Andraud (M)
G Runavot (G)
B Lhermitte (B)
G Noel (G)
S Gaillard (S)
C Villa (C)
N Desse (N)
C Rousselot-Denis (C)
I Zemmoura (I)
E Cohen-Moyal (E)
E Uro-Coste (E)
F Dhermain (F)

Références

Genome Med. 2016 Jun 20;8(1):69
pubmed: 27323951
Mol Cell Biol. 2015 Aug;35(16):2818-30
pubmed: 26055325
Mol Cell Biol. 1996 Jul;16(7):3765-72
pubmed: 8668193
J Neurooncol. 2017 Nov;135(2):381-390
pubmed: 28755323
Acta Neuropathol. 2016 Oct;132(4):625-34
pubmed: 27573687
J Physiol. 1938 Nov 14;94(2):227-31
pubmed: 16995039
Oncotarget. 2015 Jun 30;6(18):16543-58
pubmed: 26001292
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Nat Commun. 2015 Jul 06;6:7538
pubmed: 26143912
Neuro Oncol. 2014 Sep;16(9):1244-54
pubmed: 24723566
Nat Struct Mol Biol. 2015 Nov;22(11):875-80
pubmed: 26581522
J Theor Biol. 1973 Sep 14;41(1):181-90
pubmed: 4754905
Trends Cancer. 2015 Oct 1;1(2):145-156
pubmed: 26645051
Clin Cancer Res. 2005 Jan 1;11(1):217-25
pubmed: 15671549
Cancer Res. 1999 Sep 1;59(17):4175-9
pubmed: 10485449
PLoS One. 2012;7(10):e45950
pubmed: 23071531
Oncogene. 2005 Nov 24;24(53):7893-901
pubmed: 16116482
Acta Neuropathol. 2017 Jun;133(6):1001-1016
pubmed: 28255664
Am J Pathol. 2011 Oct;179(4):1608-15
pubmed: 21888887
Nat Biotechnol. 2009 Dec;27(12):1181-5
pubmed: 19935656
Int J Cancer. 2015 Apr 1;136(7):1546-58
pubmed: 25175359
Cancer Res. 2005 Apr 1;65(7):2730-7
pubmed: 15805272
Clin Cancer Res. 2015 Nov 1;21(21):4780-5
pubmed: 26362996
Nat Genet. 2017 Mar;49(3):349-357
pubmed: 28135248
Science. 2011 Jul 22;333(6041):425
pubmed: 21719641
Science. 2015 Jan 16;347(6219):273-7
pubmed: 25593184
Nat New Biol. 1972 Oct 18;239(94):197-201
pubmed: 4507727
Br J Cancer. 2014 Nov 11;111(10):2024-32
pubmed: 25314060
Curr Pharm Des. 2014;20(41):6466-71
pubmed: 24975611
Nat Med. 1997 Nov;3(11):1271-4
pubmed: 9359704
Lancet. 2003 Mar 8;361(9360):836-8
pubmed: 12642053
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
Genetics. 1941 Mar;26(2):234-82
pubmed: 17247004
Cancer Res. 2005 Apr 1;65(7):2722-9
pubmed: 15805271
Acta Neuropathol. 2015 May;129(5):679-93
pubmed: 25783747
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248

Auteurs

Nathalie Grandin (N)

Laboratoire GReD, CNRS UMR6293, INSERM U1103, Faculty of Medicine, Bldg CRBC, 2nd floor, 28 place Henri Dunant, 63001, Clermont-Ferrand, France.
Université Clermont Auvergne, 63001, Clermont-Ferrand, France.

Bruno Pereira (B)

CHU Clermont-Ferrand, Biostatistics unit, DRCI, 63003, Clermont-Ferrand, France.

Camille Cohen (C)

Université de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, LabEx DEVweCAN, Institut NeuroMyoGène (INMG), Lyon, France.

Pauline Billard (P)

Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Institut de Biopathologie moléculaire, UF de biologie moléculaire, Centre de Bio-Pathologie Est, Hospices Civils de Lyon, Lyon, France.

Caroline Dehais (C)

AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de neurologie 2-Mazarin, 75013, Paris, France.

Catherine Carpentier (C)

Sorbonne Université, INSERM, CNRS, UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Ahmed Idbaih (A)

AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de neurologie 2-Mazarin, 75013, Paris, France.
Sorbonne Université, INSERM, CNRS, UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Franck Bielle (F)

Sorbonne Université, INSERM, CNRS, UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, 75013, Paris, France.

François Ducray (F)

Hospices Civils de Lyon, Hôpital Pierre Wertheimer, Service de Neuro-oncologie, Bron, France.
Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France.

Dominique Figarella-Branger (D)

APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
Aix-Marseille University, CNRS, INP, Institut Neurophysiopathologie, Marseille, France.

Jean-Yves Delattre (JY)

AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de neurologie 2-Mazarin, 75013, Paris, France.
Sorbonne Université, INSERM, CNRS, UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Marc Sanson (M)

AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de neurologie 2-Mazarin, 75013, Paris, France.
Sorbonne Université, INSERM, CNRS, UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Patrick Lomonte (P)

Université de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, LabEx DEVweCAN, Institut NeuroMyoGène (INMG), Lyon, France.

Delphine Poncet (D)

Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Institut de Biopathologie moléculaire, UF de biologie moléculaire, Centre de Bio-Pathologie Est, Hospices Civils de Lyon, Lyon, France.

Pierre Verrelle (P)

Université Clermont Auvergne, 63001, Clermont-Ferrand, France. pierre.verrelle@clermont.unicancer.fr.
CIMB, CNRS UMR9187, INSERM U1196, Institut Curie, 15 rue Georges Clemenceau, 91405, Orsay, France. pierre.verrelle@clermont.unicancer.fr.
Département de Radiothérapie, Centre Jean Perrin, Clermont-Ferrand, France. pierre.verrelle@clermont.unicancer.fr.
Département de Radiothérapie, Institut Curie, Paris, France. pierre.verrelle@clermont.unicancer.fr.

Michel Charbonneau (M)

Laboratoire GReD, CNRS UMR6293, INSERM U1103, Faculty of Medicine, Bldg CRBC, 2nd floor, 28 place Henri Dunant, 63001, Clermont-Ferrand, France. michel.charbonneau@uca.fr.
Université Clermont Auvergne, 63001, Clermont-Ferrand, France. michel.charbonneau@uca.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH